Yu Qian

949 total citations
37 papers, 703 citations indexed

About

Yu Qian is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Yu Qian has authored 37 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 12 papers in Oncology and 9 papers in Cell Biology. Recurrent topics in Yu Qian's work include Bone Metabolism and Diseases (17 papers), Bone health and treatments (9 papers) and Hippo pathway signaling and YAP/TAZ (8 papers). Yu Qian is often cited by papers focused on Bone Metabolism and Diseases (17 papers), Bone health and treatments (9 papers) and Hippo pathway signaling and YAP/TAZ (8 papers). Yu Qian collaborates with scholars based in China, United States and Australia. Yu Qian's co-authors include Wanlei Yang, Weiqi Han, Tan Zhang, An Qin, Xuanyuan Lu, Yewei Jia, Jiawei Jiang, Jiake Xu, Xiucheng Li and Ziyi Wang and has published in prestigious journals such as Nature Neuroscience, Scientific Reports and The FASEB Journal.

In The Last Decade

Yu Qian

36 papers receiving 698 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu Qian China 17 450 116 116 104 84 37 703
Franziska Busch Germany 7 405 0.9× 107 0.9× 51 0.4× 126 1.2× 95 1.1× 10 1.0k
Zhiping Miao China 13 482 1.1× 69 0.6× 51 0.4× 209 2.0× 45 0.5× 28 726
Jiachen Lin China 11 329 0.7× 39 0.3× 111 1.0× 62 0.6× 60 0.7× 20 652
Kazuhisa Nishishita Japan 14 402 0.9× 92 0.8× 54 0.5× 98 0.9× 115 1.4× 34 617
Noritaka Matsuo Japan 18 410 0.9× 74 0.6× 129 1.1× 109 1.0× 31 0.4× 44 897
Zhe Wei China 18 492 1.1× 76 0.7× 87 0.8× 55 0.5× 29 0.3× 38 949
Junlan Huang China 17 290 0.6× 66 0.6× 55 0.5× 69 0.7× 67 0.8× 31 778
Jihoon Han South Korea 14 726 1.6× 103 0.9× 39 0.3× 269 2.6× 46 0.5× 22 1.0k

Countries citing papers authored by Yu Qian

Since Specialization
Citations

This map shows the geographic impact of Yu Qian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Qian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Qian more than expected).

Fields of papers citing papers by Yu Qian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Qian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Qian. The network helps show where Yu Qian may publish in the future.

Co-authorship network of co-authors of Yu Qian

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Qian. A scholar is included among the top collaborators of Yu Qian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Qian. Yu Qian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Xin, et al.. (2025). Pharmacological regulators of Hippo pathway: Advances and challenges of drug development. The FASEB Journal. 39(6). e70438–e70438. 2 indexed citations
2.
Chen, Xin, et al.. (2025). Role of YAP/TAZ in bone diseases: A transductor from mechanics to biology. Journal of Orthopaedic Translation. 51. 13–23. 6 indexed citations
3.
Chen, Zhuolin, Xuanyuan Lu, Jiewen Zheng, et al.. (2024). Targeted inhibition of STAT3 (Tyr705) by xanthatin alleviates osteoarthritis progression through the NF-κB signaling pathway. Biomedicine & Pharmacotherapy. 174. 116451–116451. 7 indexed citations
4.
Zhou, Hongyi, Ziang Xie, Yu Qian, et al.. (2024). FTO-mediated SMAD2 m6A modification protects cartilage against Osteoarthritis. Experimental & Molecular Medicine. 56(10). 2283–2295. 3 indexed citations
5.
Huang, Yuxin, et al.. (2023). Cornus officinalis: a potential herb for treatment of osteoporosis. Frontiers in Medicine. 10. 1289144–1289144. 10 indexed citations
6.
Xu, Rongjian, Xuewen Liu, Yufeng Zhang, et al.. (2023). Activating transcriptional coactivator with PDZ-binding motif by (R)-PFI-2 attenuates osteoclastogenesis and prevents ovariectomized-induced osteoporosis. Biochemical Pharmacology. 219. 115964–115964. 4 indexed citations
7.
Li, Fenglin, Xiang Zhang, Shihui Mao, et al.. (2021). MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway. EBioMedicine. 69. 103441–103441. 10 indexed citations
8.
Yang, Qichang, Peng Sun, Tan Zhang, et al.. (2021). Hinokitiol inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced bone loss in vivo. International Immunopharmacology. 96. 107619–107619. 7 indexed citations
9.
Yang, Wanlei, Xuanyuan Lu, Tan Zhang, et al.. (2021). TAZ inhibits osteoclastogenesis by attenuating TAK1/NF-κB signaling. Bone Research. 9(1). 33–33. 42 indexed citations
10.
Li, Xiucheng, et al.. (2021). Galangin suppresses RANKL‐induced osteoclastogenesis via inhibiting MAPK and NF‐κB signalling pathways. Journal of Cellular and Molecular Medicine. 25(11). 4988–5000. 23 indexed citations
11.
Zhang, Tan, Lei He, Wanlei Yang, et al.. (2020). Byakangelicin inhibits IL-1β–induced mouse chondrocyte inflammation in vitro and ameliorates murine osteoarthritis in vivo. International Immunopharmacology. 85. 106605–106605. 12 indexed citations
12.
Sun, Peng, Qichang Yang, Yewei Jia, et al.. (2020). <p>Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo</p>. Drug Design Development and Therapy. Volume 14. 4189–4203. 5 indexed citations
13.
Mei, Zhendong, Xin Dong, Yu Qian, et al.. (2020). Association between the metabolome and bone mineral density in a Chinese population. EBioMedicine. 62. 103111–103111. 39 indexed citations
14.
Zhu, Jiling, Peng Sun, Qichang Yang, et al.. (2020). <p>Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo</p>. Drug Design Development and Therapy. Volume 14. 3435–3447. 15 indexed citations
15.
Jia, Yewei, Cong Pang, Jiawei Jiang, et al.. (2019). Garcinol Suppresses IL-1β-Induced Chondrocyte Inflammation and Osteoarthritis via Inhibition of the NF-κB Signaling Pathway. Inflammation. 42(5). 1754–1766. 37 indexed citations
16.
Jia, Yewei, Jiawei Jiang, Xuanyuan Lu, et al.. (2018). Garcinol suppresses RANKL‐induced osteoclastogenesis and its underlying mechanism. Journal of Cellular Physiology. 234(5). 7498–7509. 18 indexed citations
17.
Yang, Wanlei, Weiqi Han, An Qin, et al.. (2017). The emerging role of Hippo signaling pathway in regulating osteoclast formation. Journal of Cellular Physiology. 233(6). 4606–4617. 77 indexed citations
18.
Kuek, Vincent, Zhifan Yang, Shek Man Chim, et al.. (2016). NPNT is Expressed by Osteoblasts and Mediates Angiogenesis via the Activation of Extracellular Signal-regulated Kinase. Scientific Reports. 6(1). 36210–36210. 24 indexed citations
19.
Liu, Mei, Xueying Fan, Chao Tang, et al.. (2016). Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Letters. 378(1). 38–50. 61 indexed citations
20.
Qian, Yu, Zhen Lin, Jimin Chen, et al.. (2009). Natural bone collagen scaffold combined with OP‐1 for bone formation induction in vivo. Journal of Biomedical Materials Research Part B Applied Biomaterials. 90B(2). 778–788. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Franziska Busch Breakdown of academic impact, for papers by Zhiping Miao Breakdown of academic impact, for papers by Jiachen Lin Breakdown of academic impact, for papers by Kazuhisa Nishishita Breakdown of academic impact, for papers by Noritaka Matsuo Breakdown of academic impact, for papers by Zhe Wei Breakdown of academic impact, for papers by Junlan Huang Breakdown of academic impact, for papers by Jihoon Han
Rankless by CCL
2026